FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Can Vet J / Warfarin: a review with emphasis on its use in the horse.
The Canadian veterinary journal = La revue veterinaire canadienne1983; 24(7); 211-213;

Warfarin: a review with emphasis on its use in the horse.

Abstract: Warfarin or dicoumarol prevents the production of functional clotting factors II, VII, IX and X. Navicular disease and thrombophlebitis are examples of equine thrombotic diseases in which warfarin has been used therapeutically. The initiation of anticoagulant therapy is relatively simple but attending veterinarians must be aware of the potential risks in order to minimize them. These risks include epistaxis, bleeding into the gastrointestinal tract and at the venipuncture site, and increased susceptibility to hematoma formation following local trauma. Vitamin K, especially vitamin K(1) is a swift and specific antidote for warfarin toxicity.
Get Full Text
Publication Date: 1983-07-01 PubMed ID: 17422277PubMed Central: PMC1790352
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article provides a review of the use of Warfarin, an anticoagulant medication, particularly in the treatment of certain equine diseases associated with blood clotting. Warfarin works by inhibiting the production of clotting factors, though its use comes with potential risks.

Role of Warfarin

  • Warfarin is an anticoagulant that inhibits the production of certain clotting factors such as II, VII, IX, and X. These factors are crucial in blood coagulation and their reduced availability inhibits the ability of blood to form clots.
  • As a result, Warfarin can be used therapeutically in treating thrombotic conditions or diseases—conditions characterized by blood clot formation. In the context of this study, Warfarin has been used in treating equine thrombotic diseases such as navicular disease, and thrombophlebitis.

Management of Warfarin Therapy

  • The initiation of Warfarin therapy is relatively simple, however, the attending veterinarians must be aware of the potential risks to effectively manage and minimize them. This awareness helps in providing necessary safety measures and preparation for potential side effects.

Risks Associated with Warfarin Usage

  • The potential risks or side-effects associated with Warfarin usage as mentioned in the research include: epistaxis (nose bleeding), bleeding into the gastrointestinal tract, bleeding at the site of venipuncture (where blood is drawn for tests), and an increased susceptibility to hematoma formation (localized collection of blood outside blood vessels due to blood leakage) post local trauma.

Treatment for Warfarin Toxicity

  • For times when the toxicity due to Warfarin overdose exists, the researchers mention Vitamin K, particularly Vitamin K(1), as a swift and specific antidote. This means vitamin K(1) could be promptly administrated in case of excessive Warfarin intake to counteract its effects and reduce the harm done to the patient.

Cite This Article

APA
Vrins A, Carlson G, Feldman B. (1983). Warfarin: a review with emphasis on its use in the horse. Can Vet J, 24(7), 211-213.

Publication

The Canadian veterinary journal = La revue veterinaire canadienne
ISSN: 0008-5286
NlmUniqueID: 0004653
Country: Canada
Language: English
Volume: 24
Issue: 7
Pages: 211-213

Researcher Affiliations

Vrins, A
    Carlson, G
      Feldman, B

        References

        This article includes 17 references
        1. Kakkar VV. Prevention of venous thromboembolism.. Clin Haematol 1981 Jun;10(2):543-82.
          pubmed: 6172228
        2. Feldman BF. Coagulopathies in small animals.. J Am Vet Med Assoc 1981 Sep 15;179(6):559-63.
          pubmed: 6973562
        3. Mount ME, Feldman BF, Buffington T. Vitamin K and its therapeutic importance.. J Am Vet Med Assoc 1982 Jun 1;180(11):1354-6.
          pubmed: 7096182
        4. Scott EA, Byars TD, Lamar AM. Warfarin anticoagulation in the horse.. J Am Vet Med Assoc 1980 Dec 1;177(11):1146-51.
          pubmed: 7440316
        5. WRIGHT HP, KUBIK MM, HAYDEN M. Recanalization of thrombosed arteries under anticoagulant therapy.. Br Med J 1953 May 9;1(4818):1021-3.
          pubmed: 13032608doi: 10.1136/bmj.1.4818.1021google scholar: lookup
        6. BLAKE TM, WOOD EG Jr, O'MOORE D, NEEL RG. The vasodilating effects of coumarin derivatives.. Am J Med Sci 1962 May;243:598-602.
          pubmed: 13869764doi: 10.1097/00000441-196205000-00008google scholar: lookup
        7. O'REILLY RA, AGGELER PM, LEONG LS. STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN.. J Clin Invest 1963 Oct;42(10):1542-51.
          pubmed: 14074349doi: 10.1172/JCI104839google scholar: lookup
        8. HELLEMANS J, VORLAT M, VERSTRAETE M. SURVIVAL TIME OF PROTHROMBIN AND FACTORS VII, IX AND X AFTER COMPLETELY SYNTHESIS BLOCKING DOSES OF COUMARIN DERIVATIVES.. Br J Haematol 1963 Oct;9:506-12.
          pubmed: 14076133doi: 10.1111/j.1365-2141.1963.tb05475.xgoogle scholar: lookup
        9. Mackie MJ, Douglas AS. Oral anticoagulants in arterial disease.. Br Med Bull 1978 May;34(2):177-82.
          pubmed: 350342doi: 10.1093/oxfordjournals.bmb.a071489google scholar: lookup
        10. Colles CM. Ischaemic necrosis of the navicular bone and its treatment.. Vet Rec 1979 Feb 17;104(7):133-7.
          pubmed: 452348doi: 10.1136/vr.104.7.133google scholar: lookup
        11. Scott EA, Sandler GA, Byars TD. Warfarin: effects on anticoagulant, hematologic, and blood enzyme values in normal ponies.. Am J Vet Res 1979 Jan;40(1):142-6.
          pubmed: 453677
        12. Colles CM. A preliminary report on the use of warfarin in the treatment of navicular disease.. Equine Vet J 1979 Jul;11(3):187-90.
          pubmed: 488067doi: 10.1111/j.2042-3306.1979.tb01338.xgoogle scholar: lookup
        13. Seller EM, Lang-Sellers ML, Koch-Weser J. Comparative warfarin binding to albumin from various species.. Biochem Pharmacol 1977 Dec 15;26(24):2445-7.
          pubmed: 563722doi: 10.1016/0006-2952(77)90455-5google scholar: lookup
        14. Scott EA, Sandler GA, Byars TD. Warfarin: effects of intravenous loading doses and vitamin K on warfarin anticoagulation in the pony.. Am J Vet Res 1978 Dec;39(12):1888-91.
          pubmed: 749570
        15. Colles CM, Hickman J. The arterial supply of the navicular bone and its variations in navicular disease.. Equine Vet J 1977 Jul;9(3):150-4.
          pubmed: 891518doi: 10.1111/j.2042-3306.1977.tb04009.xgoogle scholar: lookup
        16. Deykin D. Warfarin therapy. 1.. N Engl J Med 1970 Sep 24;283(13):691-4.
          pubmed: 4916914doi: 10.1056/NEJM197009242831307google scholar: lookup
        17. Kahn RA, Johnson SA, DeGraff AF. Effects of sodium warfarin on capillary ultrastructure.. Am J Pathol 1971 Oct;65(1):149-56.
          pubmed: 5096364

        Citations

        This article has been cited 2 times.
        1. Ayala I, Rodríguez MJ, Martos N, Zilberschtein J, Ruíz I, Motas M. Fatal brodifacoum poisoning in a pony. Can Vet J 2007 Jun;48(6):627-9.
          pubmed: 17616062
        2. Boermans HJ, Johnstone I, Black WD, Murphy M. Clinical signs, laboratory changes and toxicokinetics of brodifacoum in the horse. Can J Vet Res 1991 Jan;55(1):21-7.
          pubmed: 1884280
        Subscribe to our newsletter
        Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.